Biocryst Pharmaceuticals stock had its Relative Strength (RS) Rating upgraded from 88 to 92 Wednesday.
When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength. This unique rating measures market leadership by showing how a stock's price movement over the last 52 weeks measures up against that of the other stocks in our database.
Decades of market research reveals that the best stocks tend to have an RS Rating of at least 80 as they begin their biggest price moves.
Looking For Winning Stocks? Try This Simple Routine
Is Biocryst Pharmceutical Stock A Buy?
Biocryst Pharmaceuticals stock had a failed breakout from a cup-shaped base back in February. While the biotech stock is not near an ideal entry right now, see if it is able to form and break out of a proper chart pattern. Read "Looking For The Next Big Stock Market Winners? Start With These 3 Steps" for more tips.
Earnings growth dropped in the most recent report from 0% to -21%. But revenue gains moved higher, from 572% to 1,073%.
Biocryst Pharmaceuticals stock earns the No. 48 rank among its peers in the Medical-Biomed/Biotech industry group. Pacira Pharmaceuticals, Amphastar Pharmaceutcls and Vertex Pharmaceuticals are among the top 5 highly rated stocks within the group. For more industry group news, check out "Biotech And Pharmaceutical Industry And Stock News."
